#### 1 Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in

### 2 type II and type III spinal muscular atrophy patients

- 3 Iddo Magen<sup>1,2</sup><sup>\$</sup>, Sharon Aharoni<sup>3,4</sup><sup>\$</sup>, Nancy Sarah Yacovzada<sup>1,2</sup>, Itay Tokatly Latzer<sup>4,5</sup>, Christiano R R
- 4 Alves<sup>6</sup>, Liora Sagi<sup>4,5</sup>, Aviva Fattal-Valevski<sup>4,5</sup>, Kathryn J Swoboda<sup>6</sup>, Jacob Katz<sup>4,7</sup>, Elchanan
- 5 Bruckheimer<sup>4,8</sup>, Yoram Nevo<sup>3,4</sup>\* and Eran Hornstein<sup>1,2</sup>\*
- 6 <sup>1</sup> Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel
- 7 <sup>2</sup> Department of Molecular Neuroscience, Weizmann Institute of Science, Rehovot, Israel
- <sup>3</sup> Institute of Pediatric Neurology, Schneider Children's Medical Center of Israel, Petach Tikva, Israel
- 9 <sup>4</sup> Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- <sup>5</sup> Pediatric Neurology Institute, Dana-Dwek Children's Hospital, Tel Aviv Medical Center, Tel Aviv,
- 11 Israel.
- <sup>6</sup> Department of Neurology, Center for Genomic Medicine, Massachusetts General Hospital, Boston,
- 13 MA, USA.
- <sup>7</sup> Division of Department of Anesthesia, Schneider Children's Medical Center of Israel, Petach Tikva,
   Israel
- <sup>8</sup> Cardiology Institute, Schneider Children's Medical Center of Israel, Petach Tikva, Israel
- 17
- 18
- 19 \$ Equal contribution
- 20 \* To whom correspondence should be addressed:
- 21 <u>yoramne@clalit.org.il</u> or <u>eran.hornstein@weizmann.ac.il</u>

#### 22 Abstract

Objective: The antisense oligonucleotide nusinersen (spinraza) regulates splicing of the *survival motor neuron 2 (SMN2)* messenger RNA to increase survival motor neuron (SMN) protein expression and has improved ventilator free survival and motor function outcomes in infantile onset forms of SMA, treated early in the course of the disease. However, the response in later onset forms of SMA is highly variable and dependent on symptom severity and disease duration at treatment initiation. Therefore, we aimed to identify novel noninvasive biomarkers that could predict the response to nusinersen in type II and III SMA patients.

30 **Methods:** This is a multi-center longitudinal cohort study including a total of 34 type II or III SMA 31 patients. We applied unbiased next-generation sequencing to identify cell-free microRNAs in the 32 cerebrospinal fluid (CSF) as candidate biomarkers to predict response to nusinersen. Motor function, 33 assessed by the Hammersmith Functional Motor Scale Expanded (HFMSE), was considered the 34 primary clinical outcome. HFMSE was conducted at baseline and 6 months post initiation of 35 nusinersen therapy. Patients with an improvement  $\geq$  3 points or no change or decline < 0 points in the 36 HFMSE total score were considered to be responders or non-responders, respectively.

**Results:** Lower baseline levels of two muscle microRNAs (miR-206 and miR-133), alone or in
combination, were associated with the pre-determined clinical response to nusinersen after 6 months
therapy. Moreover, miR-206 levels were inversely correlated with the HFMSE score.

40 **Conclusions:** Lower miR-206 and miR-133 in the CSF predict more robust clinical response to 41 nusinersen treatment in later onset SMA patients. These novel findings have high clinical relevance for 42 identifying early treatment response to nusinsersen in later onset SMA patients and call to test the 43 ability of miRNAs to predict more sustained long-term benefit.

44

#### 45 Introduction

Spinal muscular atrophy (SMA) is a genetic pediatric disease with an incidence of ~ 1/11,000 live 46 births, and a carrier frequency of  $\sim 1/40^{1, 2}$ . SMA is characterized by muscle weakness and atrophy, 47 resulting from progressive degeneration of lower motor neurons in the spinal cord and the brain stem 48 49 nuclei. Historically, SMA subtype classification is based on age of onset and the maximum motor 50 abilities achieved. SMA type I patients have onset in early infancy and never sit. SMA type II patients 51 have later infantile onset but never walk. SMA type III patients have more variable childhood onset, and achieve the ability to walk<sup>3</sup>. The cause of SMA are homozygous deletion or compound 52 53 heterozygous mutation involving exon 7 of the Survival Motor Neuron 1 (SMN1) gene. However, 54 SMN1 has a paralogous gene named SMN2, which undergoes alternative splicing, including the removal of exon 7, and produces ~10% functional SMN protein <sup>4, 5</sup>. Therefore, the number of SMN2 55 copies correlates with phenotypic severity and is the main genetic disease modifier  $^{6-8}$ . 56

57 Nusinersen was the first drug approved by the US Food and Drug Administration (FDA) to precisely 58 treat SMA. The drug is a synthetic antisense oligonucleotide that modulates pre-messenger RNA 59 splicing of the SMN2 gene. Despite the advance of novel molecular and gene therapies for SMA, 60 nusinersen remains to this day the most widely used and available SMA disease-modifying therapy. Nusinersen has been proven efficient in young type I SMA patients, and it is dramatically changing the 61 natural history of this disease<sup>9, 10</sup>. However, the degree of response in subjects with later-onset forms of 62 63 SMA (type II and III) is highly dependent on age of treatment, time from symptom onset and severity of denervation. Therefore, better understanding of the variable treatment response in this population is 64 65 important and novel biomarkers to predict treatment response to nusinersen in type II or type III SMA subjects are critical. 66

67 A main interest of our group has been to investigate the profile of microRNAs (miRNAs) in the 68 disease context, since several endogenous non-coding RNAs are highly expressed in both neuronal and 69 muscular tissues. Previous evidence indicates that some miRNAs are essential for motor neuron 70 survival, and low expression levels have been demonstrated in motor neurons from an SMA mouse 71 model and in postmortem neuronal tissues from patients with another motor neuron disease, amyotrophic lateral sclerosis (ALS) 11-13. Moreover, miRNAs known as myomiRs, such as miR-72 73 1/133a/133b/206, are mainly expressed in the skeletal muscle, where they are thought to play an important role in myoblast proliferation and differentiation<sup>14, 15</sup>. Recent studies have demonstrated that 74 75 the expression of myomiRs can be detected and differentially expressed in biofluids from ALS patients

when compared to healthy controls <sup>16-18</sup>, suggesting a potential role of these molecules in the early diagnosis of the disease. In addition, serum myomiRs are in correlation with the response to ongoing therapy in SMA type II and III<sup>19</sup>. However, a prospective study that identifies responders to Nusinersen therapy, based on a basal, pre-treatment, molecular profile, was not yet reported.

On the basis of understanding the miRNA role in motor neuron diseases<sup>11-13</sup> and potential discovery of 80 novel biomarkers<sup>20-22</sup>, we sought to test the utility of specific miRNAs in the cerebrospinal fluid (CSF) 81 82 as candidate molecules to predict a positive clinical response to nusinersen in type II/III SMA patients. 83 We applied for the first time an unbiased next-generation sequencing to investigate the potential of 84 cell-free microRNAs in the CSF of SMA patients receiving nusinersen therapy. Our novel findings 85 indicate that the muscle miRNAs miR-206 and miR-133 are associated with the response to nusinersen 86 treatment and, therefore, have the potential to help predict, when combined with other indicators, 87 whether or not a given SMA patient is more or less likely to show an early response.

88

#### 89 Materials and Methods

Subjects, Ethics and Motor Function. This study includes a cohort of 45 type II or type III SMA 90 91 patients, that were recruited between November 2016 and July 2019 in three different medical centers: 92 Schneider Children's Medical Center of Israel (Israel, n=13), Dana-Dwek Children's Hospital, Tel Aviv 93 Medical Center (Israel, n=20) and Massachusetts General Hospital (MA, US, n=12). Approval for the 94 study was provided by local ethical committees (Schneider Medical Center: RMC-0060-18; Tel Aviv 95 Medical Center: 0347-18-TLV; Massachusetts General Hospital MGH #2016P000469), and it was 96 conducted in accordance with the International Conference on Harmonization guidelines for Good 97 Clinical Practice and the World Medical Association Declaration of Helsinki. Written informed 98 parental consent were obtained from all participants. Nusinersen was administered on days 1, 15, 29, 99 and 64 for the loading phase, followed by an additional maintenance dose after 4 additional months 100 from the loading phase. Baseline demographic and clinical data were collected. Motor function was assessed at each visit by a physical therapist with SMA clinical trial training <sup>23</sup> using Hammersmith 101 Functional Motor Scale Expanded (HFMSE)<sup>24</sup>. CSF samples were collected on day 1 and 183 right 102 before the nusinersen injection in each day and were stored frozen at  $-80^{\circ}$ C. 103

Inclusion and exclusion criteria. All 45 patients had a genetic diagnosis for SMA, and were followed up to this point. They were included in the study after verifying that for both day 1 and day 183, they had non-hemolyzed CSF samples and record of their HFMSE score.

An improvement at the HFMSE final score  $\geq 3$  points was considered clinically significant<sup>25, 26</sup> and patients with such an improvement were considered as 'responders', while those with a change of HFMSE final score  $\leq 0$  were considered as 'non-responders'. Samples from 11 patients with an indefinite clinical response to nusinersen (HFMSE improvement of 1 or 2 points) were processed, but were later excluded from further analysis, arriving a final study size of 34 patients. Based on power analysis calculations, we found that this number was sufficient to obtain an effect size of 3 for change in miRNA level with a power of 95% and a p-value of 0.01.

114

Small RNA Next Generation Sequencing. Total RNA was extracted from CSF using the miRNeasy 115 116 micro kit (Qiagen, Hilden, Germany) and quantified with Qubit fluorometer using RNA broad range 117 (BR) assay kit (Thermo Fisher Scientific, Waltham, MA). For small RNA next generation sequencing 118 (RNA-seq), libraries were prepared from 7.5 ng of total RNA using the QIAseq miRNA Library Kit 119 and QIAseq miRNA NGS 48 Index IL (Qiagen), by an experimenter who was blinded to the identity of 120 samples. Samples were randomly allocated to library preparation and sequencing in batches. Precise 121 linear quantification of miRNA is achieved by using unique molecular identifiers (UMIs), of random 12-nucleotide after 3' and 5' adapter ligation, within the reverse transcription primers <sup>20</sup>. cDNA 122 123 libraries were amplified by PCR for 22 cycles, with a 3' primer that includes a 6-nucleotide unique 124 index, followed by on-bead size selection and cleaning. Library concentration was determined with 125 Qubit fluorometer (dsDNA high sensitivity assay kit; Thermo Fisher Scientific, Waltham, MA) and library size with Tapestation D1000 (Agilent). Libraries with different indices were multiplexed and 126 127 sequenced on NextSeq 500/550 v2 flow cell or Novaseq SP100 (Illumina), with 75bp single read and 128 6bp index read. Fastq files were de-multiplexed using the user-friendly transcriptome analysis pipeline (UTAP)<sup>27</sup>. Human miRNAs, as defined by miRBase<sup>28</sup>, were mapped using Geneglobe Data Analysis 129 Center (Qiagen). 130

Statistical analysis. As many as 2530 individual miRNA species were aligned to the human genome (GRCh37/hg19) across all samples. miRNAs with  $\leq 100$  UMIs on average across all samples were excluded from analysis. Sequencing data were normalized with DESeq2 package<sup>29</sup> under the assumption that miRNA counts followed negative binomial distribution and data were corrected for the library preparation batch in order to reduce its potential bias. Fold-change values in miRNA abundance between responders and non-responders were calculated as the ratio of normalized counts in responders (*i.e.* patients exhibiting meaningful clinical improvement) to the normalized counts in the

non-responders (patients exhibiting lack of clinical improvement), and transformed to log base 2.
Statistical significance was determined using the Wald test.

Feature scaling to the range of [0-1] was further done for DESeq2 normalized counts of miR-133a and miR-206 by applying min-max scaling, whereby the scaled value (x') is calculated by subtracting the

142 minimum value of each feature [min(x)] from each individual observation (x), and further divided by

143 the difference between the maximum and the minimum value [max(x) - min(x)], as shown below

144 
$$x' = \frac{x - \min(x)}{\max(x) - \min(x)}$$

145

146 Scaled values were then summed to generate a devised feature termed miR-133a/206.

147 Correlation between miRNA levels and the clinical improvement in HFMSE score (HFMSE score post 148 treatment - HFMSE score pretreatment) was calculated by both linear regression, wherein the 149 improvement is a numerical value, and logistic regression, wherein the improvement is binarized into "failure" (HFMSE score change  $\leq 0$  between post and pretreatment) and "success" (HFMSE score 150 change  $\geq$  3 between post and pretreatment). Logistic regression was performed with the aod and 151 ggplot2 packages in  $R^{30}$ , either for a single explanatory variable (either one miRNA gene or a feature 152 combined of two miRNAs) or as multinomial regression with multiple explanatory variables (a 153 154 combination of different miRNAs or miRNAs and clinical features). The fitted logistic regression 155 model is an exponential model from which predicted probabilities of "success" can be calculated based on values of the explanatory variable(s). Exponential equations for all models are available in 156 157 supplementary table 1. Two values are derived from the logistic regression model: Chi-square  $(\chi^2)$ , which expresses the goodness of fit for the whole model and Akaike's information criterion 158 (AIC)<sup>31</sup>, an estimation of the model prediction error. Statistical significance was determined for 159 Spearman rho and chi-square values, with p-values < 0.05 being considered statistically significant. 160

Leave-one-out-cross-validation was performed on the logistic regression model, whereby model 161 learning was done in n-1 samples out of the total n, and tested on the leave-one-out sample, yielding a 162 predicted success probability for each sample. This procedure was repeated n times. Receiver 163 operating characteristic (ROC) curves were generated by plotting true positive rates (sensitivity), i.e. 164 165 percentage of patients classified as responders, out of the total number of responders, against false positive rates (100% - specificity), i.e. percentage of patients classified as responders, out of the total 166 167 number of non-responders, when each predicted success probability value is taken as a cut-off for 168 binary classification. Area under the curve (AUC) and its respective P-value were calculated for ROC

169 curves, given null hypothesis of AUC = 0.5. Graphs were generated with Prism 5 (GraphPad

170 Software, San Diego, California, USA).

171 **Results** 

#### 172 Next-Generation Sequencing Analysis in the CSF of SMA Patients Treated with Nusinersen

173 We sought to explore miRNAs expressed in the CSF as potential biomarkers for monitoring response 174 to nusinersen and to help determine, prior to treatment initiation, whether a patient was more or less 175 likely to respond to the therapy. We used next generation sequencing to investigate, without an *a priori* 176 bias, the comprehensive landscape of CSF miRNAs in 34 type II and type III SMA patients with 177 documented demographic and clinical information available (Table 1). We analyzed RNA-seq data 178 from CSF samples collected before treatment and analyzed these data in context of clinical response 6 179 months after initiation of nusinersen treatment. Data from additional 11 patients with HFMSE change 180 of a single or two units (1,2) were excluded.

After next generation sequencing, 2530 miRNA were annotated to the genome. Only 68 miRNA species exceeded a cut-off of  $\geq$ 100 unique molecular identifier (UMI) counts per sample, averaged on all samples. 17 out of the 68 miRNAs changed post-treatment relative to pre-treatment (p-value < 0.05, Wald test; **Figure S1**). Two miRNAs, miR-5694-5p and miR-3613-3p increased x 1.4-fold and miR-1-5p decreased by 1.6-fold. These data suggest that only minor effects were observed on miRNA profile after 6 months of nusinersen therapy.

## 187 Baseline miR-206 / miR-103 Levels Predict Beneficial Response to Nusinersen Therapy

The clinical response to nusinersen therapy is heterogeneous<sup>32</sup>. We tested whether the miRNA profile at baseline would be different between patients that clinically responded to nusinersen therapy and those that poorly responded. Responders (N=13) were defined as those demonstrating an increase of  $\geq$ 3 points<sup>26</sup> in the Hammersmith Functional Motor Scale Expanded (HFMSE) total score following six months of nusinersen treatment, whereas non-responders (N=21) were defined as those with no improvement or deterioration ( $\leq 0$  points).

In responders' CSF, two miRNAs changed in a significant manner relative to non-responders: miR-103b increased by 2.6-fold (Wald test: p = 0.002, **Figure 1**), and miR-206 decreased by 1.8-fold (p = 0.048). During these analyses, we noticed that similar to the downregulated miR-206 levels, other miRNAs that are known to be expressed mainly in the skeletal muscle (*i.e.* myomiRs) were relatively

low in CSF of responders, including the miR-1-3p, miR-133a-3p and miR-133b, with 1.4-fold, 1.6fold, and 2.2-fold, respectively.

The levels of miR-206 were negatively correlated with clinical improvement, quantified as the change in the HFMSE final score (Spearman rho = -0.43, 95% CI: -0.67 to -0.09, p = 0.01, **Figure 2A**). In addition, an orthogonal logistic regression model supported that miR-206 levels correlated with clinical response to nusinersen therapy ( $\chi^2 = 7$ , p = 0.008, Akaike's information criterion (AIC) = 42.2, **Figure 2B**).

205 We next sought to validate the model on newly introduced data. We trained a machine learning 206 procedure on 33 samples and tested the prediction on the single sample that was left out. The 'leave 207 one out cross validation' (LOOCV) procedure, was reiterated 34 times. This analysis reveals that miR-208 206 predicts response more than can be expected at random (area under the receiver operating 209 characteristic curve (ROC AUC) = 0.7, 95% CI: 0.51 - 0.88, p-value 0.06, Figure S2). None of the 210 other myomiRs (miR-1-3p, miR-133a-3p or miR-133b, Figure S3) displayed a significant correlation 211 with response to therapy. However, miR-103b levels correlated to the change in HFMSE score after 212 therapy (Figure S4). Taken together, these data suggest that myomiRs predict the response to 213 nusinersen therapy, and the miR-206 levels at baseline may predict the response to the nusinersen 214 therapy.

#### 215 Multi-Feature Classifiers of Response to Nusinersen Therapy

216 We next considered simultaneously more than a single miRNA. The correlation of miR-206 and miR-217 133a-3p to clinical improvement and classification, when both are considered explanatory variables with weighted contributions to the model (multinomial logistic regression, equation available in 218 supplementary table 1), was higher than when miR-206 was considered as a single feature ( $\chi^2 = 9$ , p = 219 0.01, AIC = 42.1; ROC AUC 0.74, 95% CI: 0.55 - 0.92, p = 0.022, Figure 3A). None of the other 220 221 miRNAs (miR-1-3p, miR-103b or miR-133b) displayed an improved prediction capacity when added 222 on to miR-206 (Figure S5A-C). Thus, a feature composed of miR-206 and miR-133a-3p levels has an 223 improved prediction capacity for nusinersen therapy response. Adding SMA type (III vs II) improved the correlation even further (<miR-206 + miR-133a-3p + SMA type>,  $\chi^2 = 12$ , p = 0.007, AIC = 224 41.35). We preserved the prediction capacity also by performing leave one out cross validation 225 226 (LOOCV) (AUC = 0.73, 95% CI: p = 0.024, Figure 3B). Input about patient sex further improved prediction (<miR-206 + miR-133a-3p + SMA type+sex>,  $\chi^2 = 14.5$ , p = 0.006, AIC = 40.7; ROC AUC 227 = 0.76, 95 CI%: 0.56 - 0.95, p = 0.01, Figure 3C), with males being less likely to respond to therapy. 228

229 Patient age did not improve prediction ( $\chi^2 = 14.9$ , p = 0.01, AIC = 42.4; ROC AUC = 0.7, 95% CI: 230 0.475 - 0.925, p > 0.05).

In addition to the multinomial regression of miR-133a and miR-206, we also devised a feature by 231 normalization of the miRNA values by min-max scaling and summation of the scaled values. The new 232 predictor, miR-133a/206, displays a  $\chi^2$  of 9 (p = 0.003, Figure 4A), with a drop in predicted model 233 errors relative to when miR-133a-3p and miR-206 are independently considered (AIC 40.2 vs. 42.1, 234 235 respectively). The single standardized feature, miR-133a/206, displays ROC AUC of 0.74 (95% CI: 0.55 - 0.92, p = 0.02, Figure 4B) and information about SMA type (II or III based on clinical 236 manifestation) and sex further improved correlation to clinical response and predictive capacity ( $\gamma^2 =$ 237 14.5, p = 0.002, AIC = 38.8; ROC AUC = 0.784, 95% CI: 0.6 - 0.97, p = 0.006, Figure 4C). In 238 239 summary, two miRNA in the CSF are able to predict response to nusinersen therapy in SMA type II 240 and III patients and may be useful for pre-treatment clinical decisions.

#### 241 Discussion

242 Given the expanding treatment options available for motor neuron diseases, the discovery of novel 243 biomarkers to help track disease progression and therapeutic response is urgent. Here, we report novel 244 findings derived from the first screening for small RNAs in the CSF of type II/III SMA patients treated 245 with nusinersen. These data demonstrate that baseline levels of the myomiRs miR-133a-3p and miR-246 206 are associated with the response to nusinersen therapy, suggesting that these myomiRs could play 247 an important role in the clinical setting to help identify those patients most likely to demonstrate a 248 more robust response to nusinersen therapy. In presenting these data, we hope to encourage 249 incorporation of examination of CSF levels of miR-133a-3p and miR-206 as well as other myomiRs in 250 longitudinal follow-up across cohorts of SMA patients receiving nusinersen or other novel therapies to 251 help validate the current findings.

252 Identifying biomarkers to track SMA progression and the response to molecular therapies is an 253 important focus of our group and others. We have previously demonstrated the usefulness of electrophysiologic measures of peripheral denervation to track peripheral motor unit integrity <sup>33, 34</sup>. 254 255 Circulating SMN protein levels is a candidate biomarker for monitoring SMA disease progression, 256 although changes in peripheral SMN levels are not expected with at least two of the three currently FDA-approved therapies <sup>35</sup>. CSF and plasma neurofilaments are markers of neuronal damage and have 257 258 been identified as a potential treatment responsive biomarker in SMA and other neurodegenerative 259 diseases, but baseline CSF or circulating neurofilament levels do not seem to necessarily predict treatment response<sup>36-39</sup>. With 3 FDA-approved therapies and the anticipation of additional emerging 260 261 treatments for SMA, comprehensive longitudinal cohort studies remain critically necessary to identify useful biomarkers that could predict the response to individual therapies. 262

263 One striking finding from our observations here is that myomiR levels were detected in the CSF and 264 that CSF levels decreased in SMA patients that responded to nusinersen, when compared to those who presented a limited response. Although the myomiRs discussed here were identified via an unbiased 265 screening approach in CSF, our data corroborate recent findings demonstrating that serum myomiRs 266 levels are readouts of nusinersen response in SMA<sup>19</sup>; We propose a model, whereby the presence of 267 myomiRs in SMA CSF could be indicating blood-CSF barrier or blood-spinal cord disruption<sup>40,41</sup>, 268 269 enabling the entrance of miRNAs that are derived from breakdown of muscle cells in the setting of acute denervation<sup>16-18</sup>. Thus, lower myomiR levels prior to treatment with nusinersen, which predicts 270

those with a better response, could reflect either reduced muscle cell breakdown and/or blood to CSF

barrier integrity or both.

273

We previously demonstrated that serum creatinine, a product of skeletal muscle creatine metabolism, was also identified as a candidate biomarker to track SMA disease progression<sup>42</sup>, and that creatinine maybe a sensitive predictor for the onset of denervation in infants with 3 *SMN2* copies <sup>42</sup>. Similarly, circulating creatine kinase (CK) levels correlate with SMA severity and decreased during nusinersen therapy<sup>43</sup>. Therefore, in the future creatine capacity to predict response to Nusinersen therapy may be tested by protein biomarkers, on their own, or in combination with miRNAs, such as miR-206/133a-3p.

In summary, the current study demonstrates that the levels of muscle microRNAs miR-206 and miR-133 in CSF can predict the clinical response to nusinersen treatment in SMA patients. These novel findings have high clinical relevance and may prove useful in helping to design appropriate protocols intended to refine and improve treatment outcomes.

#### 285 **Disclosures**

286 CRRA and KJS are inventors on a patent filed by Mass General Brigham that describes genome-287 engineering technologies to treat SMA. KJS has received clinical trial funding from AveXis/Novartis 288 and Biogen. She has received speaker fees from Biogen and has served on scientific advisory boards 289 for AveXis, Biogen, Roche/Genentech.

SA has received clinical trial funding from AveXis/Novartis Gene Therapies and Biogen and has
 served on scientific advisory boards for AveXis/Novartis Gene Therapies.

292

#### 293 Acknowledgments

294 EH is the Mondry Family Professorial Chair and Head of the Nella and Leon Benoziyo Center for Neurological Diseases. Research at Hornstein lab is supported by CReATe consortium and ALSA 295 296 (program: 'Prognostic value of miRNAs in biofluids from ALS patients'), RADALA Foundation; 297 AFM Telethon (20576); Weizmann - Brazil Center for Research on Neurodegeneration at Weizmann 298 Institute of Science; the Minerva Foundation with funding from the Federal German Ministry for 299 Education and Research, ISF Legacy Heritage Fund 828/17; Israel Science Foundation 135/16; 392/21; 300 393/21; 3497/21. Target ALS 118945; Thierry Latran Foundation for ALS Research. the European 301 Research Council under the European Union's Seventh Framework Programme (FP7/2007-

302 2013)/ERC grant agreement number 617351; ERA-Net for Research Programmes on Rare Diseases 303 (eRARE FP7) via Israel Ministry of Health; Dr. Sydney Brenner and friends, Edward and Janie 304 Moravitz, A. Alfred Taubman through IsrALS, Yeda-Sela, Yeda-CEO, Israel Ministry of Trade and Industry; Y. Leon Benoziyo Institute for Molecular Medicine, Kekst Family Institute for Medical 305 306 Genetics; David and Fela Shapell Family Center for Genetic Disorders Research; Crown Human 307 Genome Center; Nathan, Shirley, Philip and Charlene Vener New Scientist Fund; Julius and Ray Charlestein Foundation; Fraida Foundation; Wolfson Family Charitable Trust; Adelis Foundation; 308 309 Merck (United Kingdom); M. Halphen; and Estates of F. Sherr, L. Asseof, L. Fulop. NSY was 310 supported by the Israeli Council for Higher Education (CHE) via the Weizmann Data Science 311 Research Center. IM was supported by Teva Pharmaceutical Industries Ltd. as part of the Israeli 312 National Network of Excellence in Neuroscience (NNE, fellowship 117941).

- 313 CRRA was funded by MGH Executive Committee on Research. KJS was funded by NIH NICHD
- R01HD054599, NIH NINDS R21NS108015, Biogen, AveXis and Cure SMA. We are grateful to all
- the patients and families who participated in this study.

#### 316 References

321

322

329

330

331

344

345

346

347

348

349

350

351

352

356

359

360

361

362

363 364

- 317 1. Ogino S, Leonard DG, Rennert H, Wilson RB. Spinal muscular atrophy genetic testing experience at an 318 academic medical center. J Mol Diagn 2002;4:53-58.
- 319 2. Verhaart IEC, Robertson A, Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q-linked 320 spinal muscular atrophy - a literature review. Orphanet J Rare Dis 2017;12:124.
  - 3. Prior TW, Leach ME, Finanger E. Spinal Muscular Atrophy. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews((R)). Seattle (WA)1993.
- 323 4. Groen EJN, Talbot K, Gillingwater TH. Advances in therapy for spinal muscular atrophy: promises and 324 challenges. Nat Rev Neurol 2018;14:214-224.
- 325 5. Faravelli I, Nizzardo M, Comi GP, Corti S. Spinal muscular atrophy-recent therapeutic advances for an 326 old challenge. Nat Rev Neurol 2015;11:351-359.
- 327 6. Mailman MD, Heinz JW, Papp AC, et al. Molecular analysis of spinal muscular atrophy and 328 modification of the phenotype by SMN2. Genet Med 2002;4:20-26.
  - 7. Feldkotter M, Schwarzer V, Wirth R, Wienker TF, Wirth B. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet 2002;70:358-368.
- 332 8. Crawford TO, Paushkin SV, Kobayashi DT, et al. Evaluation of SMN protein, transcript, and copy 333 number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study. PLoS One 334 2012;7:e33572.
- 335 9. FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating 336 Oligonucleotides. Nucleic Acid Therapeutics 2017;27:67-69. 337
  - 10. Messina S. New Directions for SMA Therapy. Journal of Clinical Medicine 2018;7:251.
- 338 11. Emde A, Eitan C, Liou LL, et al. Dysregulated miRNA biogenesis downstream of cellular stress and 339 ALS-causing mutations: a new mechanism for ALS. EMBO J 2015;34:2633-2651.
- 340 12. Reichenstein I, Eitan C, Diaz-Garcia S, et al. Human genetics and neuropathology suggest a link 341 between miR-218 and amyotrophic lateral sclerosis pathophysiology. Science Translational Medicine 342 2019;11:eaav5264. 343
  - 13. Haramati S, Chapnik E, Sztainberg Y, et al. miRNA malfunction causes spinal motor neuron disease. Proc Natl Acad Sci U S A 2010;107:13111-13116.
  - 14. Chen J-F, Mandel EM, Thomson JM, et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nature genetics 2006;38:228-233.
    - 15. Chen J-F, Tao Y, Li J, et al. microRNA-1 and microRNA-206 regulate skeletal muscle satellite cell proliferation and differentiation by repressing Pax7. Journal of Cell Biology 2010;190:867-879.
    - 16. de Andrade HM, de Albuquerque M, Avansini SH, et al. MicroRNAs-424 and 206 are potential prognostic markers in spinal onset amyotrophic lateral sclerosis. J Neurol Sci 2016;368:19-24.
    - 17. Toivonen JM, Manzano R, Olivan S, Zaragoza P, Garcia-Redondo A, Osta R. MicroRNA-206: a potential circulating biomarker candidate for amyotrophic lateral sclerosis. PLoS One 2014;9:e89065.
- 353 18. Waller R, Goodall EF, Milo M, et al. Serum miRNAs miR-206, 143-3p and 374b-5p as potential 354 biomarkers for amyotrophic lateral sclerosis (ALS). Neurobiol Aging 2017;55:123-131. 355
  - 19. Bonanno S, Marcuzzo S, Malacarne C, et al. Circulating MyomiRs as Potential Biomarkers to Monitor Response to Nusinersen in Pediatric SMA Patients. Biomedicines 2020;8:21.
- 357 20. Coenen-Stass AML, Magen I, Brooks T, et al. Evaluation of methodologies for microRNA biomarker 358 detection by next generation sequencing. RNA Biol 2018;15:1133-1145.
  - 21. Magen I, Yacovzada N-S, Warren JD, et al. miRNA biomarkers for diagnosis of ALS and FTD, developed by a nonlinear machine learning approach. medRxiv 2021:2020.2001.2022.20018408.
  - 22. Magen I, Yacovzada NS, Yanowski E, et al. Circulating miR-181 is a prognostic biomarker for amyotrophic lateral sclerosis. bioRxiv 2021:833079.
  - 23. Glanzman AM, Mazzone ES, Young SD, et al. Evaluator Training and Reliability for SMA Global Nusinersen Trials1. J Neuromuscul Dis 2018;5:159-166.
- 24. O'Hagen JM, Glanzman AM, McDermott MP, et al. An expanded version of the Hammersmith 365 366 Functional Motor Scale for SMA II and III patients. Neuromuscul Disord 2007;17:693-697.

- 367
   25. Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus Sham Control in Later-Onset Spinal
   368
   Muscular Atrophy. N Engl J Med 2018;378:625-635.
- 369
  369 26. Swoboda KJ, Scott CB, Reyna SP, et al. Phase II open label study of valproic acid in spinal muscular atrophy. PLoS One 2009;4:e5268.
  - 27. Kohen R, Barlev J, Hornung G, et al. UTAP: User-friendly Transcriptome Analysis Pipeline. BMC bioinformatics 2019;24:154.
  - 28. Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res 2014;42:D68-73.
- 29. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data
  with DESeq2. Genome Biol 2014;15:550.
- 377 30. Multiple Logistic Regression. Applied Logistic Regression2000: 31-46.
- 378 31. Akaike H. Information Theory and an Extension of the Maximum Likelihood Principle. In: Parzen E,
  379 Tanabe K, Kitagawa G, eds. Selected Papers of Hirotugu Akaike. New York, NY: Springer New York,
  380 1998: 199-213.
  - 32. Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N Engl J Med 2017;377:1723-1732.
  - 33. Bromberg MB, Swoboda KJ. Motor unit number estimation in infants and children with spinal muscular atrophy. Muscle Nerve 2002;25:445-447.
- 385
   34. Lewelt A, Krosschell KJ, Scott C, et al. Compound muscle action potential and motor function in children with spinal muscular atrophy. Muscle Nerve 2010;42:703-708.
- 387
   35. Alves CRR, Zhang R, Johnstone AJ, et al. Whole blood survival motor neuron protein levels correlate
   388 with severity of denervation in spinal muscular atrophy. Muscle Nerve 2020;62:351-357.
- 389
   36. Darras BT, Crawford TO, Finkel RS, et al. Neurofilament as a potential biomarker for spinal muscular atrophy. Ann Clin Transl Neurol 2019;6:932-944.
  - 37. Eichelberger EJ, Alves CRR, Zhang R, et al. Increased systemic HSP70B levels in spinal muscular atrophy infants. Ann Clin Transl Neurol 2021.
- 393 38. De Vivo DC, Bertini E, Swoboda KJ, et al. Nusinersen initiated in infants during the presymptomatic
   394 stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study.
   395 Neuromuscul Disord 2019;29:842-856.
  - 39. Winter B, Guenther R, Ludolph AC, Hermann A, Otto M, Wurster CD. Neurofilaments and tau in CSF in an infant with SMA type 1 treated with nusinersen. J Neurol Neurosurg Psychiatry 2019;90:1068-1069.
- 40. Müschen LH, Osmanovic A, Binz C, et al. Cerebrospinal Fluid Parameters in Antisense
   Oligonucleotide-Treated Adult 5q-Spinal Muscular Atrophy Patients. Brain Sciences 2021;11:296.
  - 41. Somers E, Lees RD, Hoban K, et al. Vascular Defects and Spinal Cord Hypoxia in Spinal Muscular Atrophy. Annals of neurology 2016;79:217-230.
- 403
   42. Alves CRR, Zhang R, Johnstone AJ, et al. Serum creatinine is a biomarker of progressive denervation in 404
   404 spinal muscular atrophy. Neurology 2020;94:e921-e931.
- 405
   43. Freigang M, Wurster CD, Hagenacker T, et al. Serum creatine kinase and creatinine in adult spinal 406
   43. Freigang M, Wurster CD, Hagenacker T, et al. Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment. Ann Clin Transl Neurol 2021.

407

371

372

373

374

381

382

383

384

391

392

396

397

398

401

402

#### **Figure legend**

Figure 1. Pre-treatment miRNA signature associates with the response to nusinersen treatment. MA plot of differential miRNA expression in responders (N=13, patients with HFMSE change  $\geq$ 3 after 6 months of treatment) versus non-responders (N=21, HFMSE change  $\leq$ 0). Data from additional 11 patients with HFMSE change of a single or two units (1,2) were excluded. Log 2 transformed fold change (y-axis), against mean miRNA abundance (x-axis). Red: significantly changed miRNAs (p<0.05, Wald test). Higher miR-103b levels and lower muscle enriched miRNA miR-1-3p, miR-133a/b and miR-206 levels are observed in prospective nusinersen responders.

415

Figure 2. miR-206 levels are associated with clinical improvement of SMA patients following 6month nusinersen treatment. (A) Negative correlation of miR-206 levels with response to nusinersen therapy (as post-treatment – pre-treatment HFMSE score difference, Spearman rho = -0.43, p=0.01) number of patients. (B) Logistic regression of baseline miR-206 levels on clinical dichotomized response to therapy: responders (N=13, HFMSE change  $\geq$ 3 after 6 months of treatment) versus nonresponders (N=21, HFMSE change  $\leq$ 0). Statistical significance of the logistic regression model goodness of fit was assessed by the chi-square test. AIC, Akaike's information criterion.

Figure 3. A predictor, based on miR-133a and miR-206 predicts response to nusinersen. ROC
curves (A) miR-133a-3p + miR-206 (B) miR-133a-3p + miR-206 + SMA type (C) miR-133a-3p +
miR-206 + SMA type + sex with leave one out cross validation. (D) A summary of logistic regression
parameters for three multiple feature models.

Figure 4. A predictor, based on a summation of the scaled values of miR-133a and miR-206
predicts response to nusinersen. (A) Logistic regression analysis of miR-133a/206 at baseline and
clinical response to therapy after 6 months of nusinersen treatment. ROC curves based on LOOCV for
(B) miR-133a/206 and (C) miR-133a/206 with SMA type and sex. (D) A summary of logistic
regression parameters for two models.

432 Supplementary Figure 1. CSF miRNA signature after nusinersen treatment vs pre-treatment in

the same patients. MA plot showing, in the X-axis, miRNA levels averaged across CSF samples collected from 34 patients at both baseline (pre-treatment) and after 6 months of nusinersen treatment (68 samples in total). Y-axis, miRNA levels after treatment versus pre-treatment (log 2 of fold difference). Each dot represents a single miRNA gene. Dots above/below the horizontal dashed line are miRNAs with higher/lower levels post-treatment. Red dots represent miRNAs with p-value <0.05 (unadjusted).

439

Supplementary Figure 2. Receiver operating characteristic (ROC) curve based on miR-206 logistic regression and leave-one-out cross validation (LOOCV). True positive rate (sensitivity, y-axis) against false positive rate (100%-specificity, x-axis). Values of predicted success probability in each patient, as a cut-off for binary classification.

444

Supplementary Figure 3. Association of myomiRs with clinical improvement of SMA patients during nusinersen treatment. Spearman correlation of baseline miR-1-3p (A), miR-133a-3p (B) and miR-133b (C) with the difference in HFMSE score following nusinersen. Logistic regression analysis of baseline miR-1-3p (D), miR-133a-3p (E) and miR-133b (F) levels on clinical response, after 6 months of nusinersen treatment. ROC curves based on LOOCV for miR-1-3p (G), miR-133a-3p (H) and miR-133b (I).

451

452 Supplementary Figure 4. Increased miR-103b in the CSF modestly predicts clinical 453 improvement of SMA patients during nusinersen treatment. (A) miR-103b levels at baseline 454 exhibit a positive and significant correlation (Spearman rho = 0.39, p=0.02) with the difference in 455 HFMSE score following nusinersen. (B) Logistic regression analysis of miR-103b levels at baseline 456 and clinical response to therapy after 6 months of nusinersen treatment. (C) ROC curve based on 457 LOOCV for the logistic regression model.

- 458
- 459 Supplementary figure 5. ROC curves for models of (A) miR-206 + miR-103b (B) miR-206 + miR460 133b and (C) miR-206 + miR-1-3p.

	Before exclusion			After exclusion		
Cohort origin	N (% females)	Type (II/III)	Median age at treatment initiation in years (range)	N (% females)	Type (II/III)	Median age at treatment initiation in years (range)
<b>Schneider Medical</b>	13 (69%)	7/6	11.0	7 (100%)	4/3	6.4
Center			(2.3 – 19.0)			(2.9 - 17.3)
<b>Tel Aviv Medical</b>	20 (55%)	9/11	11.7	17 (59%)	8/9	11.1
Center			(1.7 - 24.4)			(1.7 - 24.4)
Massachusetts	12 (420/)	5/7	7.5	10 (40%)	4/6	11.1
<b>General Hospital</b>	12 (42%)	5/7	(2.1 - 56.6)			(2.1 - 56.6)
Total	45 (55%)	21/24	11.0	34 (53%)	16/18	11.0
			(1.7 - 56.6)			(1.7 - 56.6)

**Table 1**. Gender, age, SMA type and SMN2 copy number distribution for each cohort. 11 patients (6 from Schneider, 3 from Tel Aviv and 2 from MGH) whose change in HFMSE score between after 6 months of treatment was 1 or 2 were excluded from analysis.

Figure 1



Figure 2

Α

Linear regression miR-206 15<sub>7</sub> **AHFMSE** post-pre 10- $\rho = -0.43, p = 0.01$ 5-0 -5--10-200 400 600 0

Baseline miR-206 levels

# В

Logistic regression miR-206



Figure 3



odel	$\chi^2$	$\chi^2$ p-value	AIC
+ miR-206	9	0.01	42.1
-206 + SMA type	12	0.007	41.3
6 + SMA type + sex	14.5	0.006	40.7

Figure 4



el	$\chi^2$	$\chi^2$ p-value	AIC
3a/206	9	0.003	40.2
SMA type + sex	14.5	0.002	38.8